The physical principle is well known: magnetic field gradients generate forces and torques on magnetized materials. Using arrays of coils or external magnets (Helmholtz-type systems or robotic platforms), the following are controlled:

• Translation: the robot moves forward following the gradient.
• Orientation: the torque aligns the device to "point" towards complex trajectories.
• Mechanical interaction: vibration, rotation, or micro-impacts to act on the target.

Groups such as that of Prof. Bradley J. Nelson (ETH Zurich) and Prof. Metin Sitti (Max Planck Institute) have demonstrated precise navigation in microchannels, biological fluids, and soft tissues, with real-time control supported by imaging (fluoroscopy, ultrasound, or MRI).

The clinical goal is to reduce the stone to submillimeter fragments that the body can expel naturally. To achieve this, microrobots explore several strategies:

1. Mechanical micropercussion: vibration or rotation of an active head that generates microfractures on the stone's surface.
2. Controlled abrasion: sustained contact that “wears away” the material (calcium oxalate, phosphate, uric acid).
3. Coupling with external energy: enhancing the effect with focused ultrasound or directed microwaves.

Unlike extracorporeal shock wave lithotripsy (ESWL), where energy is transmitted from outside with dispersion, the microrobot delivers energy locally, reducing collateral damage and potentially improving efficiency in hard-to-reach stones.

Without making excessive promises, the approach offers clear theoretical advantages:

- Access to complex anatomies: narrow or tortuous renal calyces where rigid instruments fail.

- Less invasiveness: no incisions; potential reduction in pain and infections.

- Localized energy: less impact on the surrounding renal parenchyma.

- Personalized procedures: trajectory and strategy adapted to each patient.

However, these advantages must be demonstrated in comparative clinical trials against current standards.

A critical challenge is the robot's design. It must be:

• Biocompatible (medical-grade polymers, non-stick coatings).
• Resistant to varying urinary environments (pH, crystals, biofilm).
• Precisely controllable without interference.
• Recoverable or biodegradable to prevent retention.

Soft robots that deform to navigate without damaging tissues, and hybrid systems with encapsulated magnetic cores, are being investigated. Some prototypes incorporate minimal sensors or rely on external imaging to close the control loop.

Although the direct application of magnetic microrobots for kidney stone fragmentation is still in a preclinical consolidation phase, the field rests on a solid scientific foundation developed over more than a decade. Researchers such as Bradley J. Nelson have consistently demonstrated the feasibility of magnetic microrobots capable of navigating with high precision within complex biological environments, particularly in endovascular contexts where millimeter-level control is critical. In parallel, the work of Metin Sitti has expanded the paradigm to include bio-inspired systems and soft structures capable of moving through biological fluids with a degree of adaptability that reduces the risk of tissue damage. These advances are not isolated. Publications in high-impact journals such as Science Robotics, Nature Communications, and Advanced Materials have rigorously documented the remote control of microrobots using magnetic fields, as well as their ability to perform tasks such as targeted drug delivery, microstructure manipulation, and navigation in dynamic physiological media. Taken together, these results establish not only the physical feasibility of the approach, but also its potential for transfer to clinical applications in urology, where precision and access to complex cavities are crucial.

One of the most critical elements for the clinical implementation of these systems is the ability to navigate safely in real time. This requires the integration of medical imaging technologies that allow the microrobot to be located and tracked within the body. In practice, different modalities are being explored, each with its own advantages and limitations. Fluoroscopy offers high spatial resolution but involves exposure to ionizing radiation; ultrasound, on the other hand, provides a portable and radiation-free alternative, although with lower resolution in certain contexts; while magnetic resonance imaging (MRI) stands out for its excellent tissue contrast, although it introduces significant restrictions on the use of magnetic materials. Overlaid on this imaging infrastructure is an increasingly sophisticated layer of computational control. Current systems integrate trajectory planning algorithms capable of anticipating and correcting deviations caused by physiological factors such as urinary flow or respiratory movements. In this context, artificial intelligence is beginning to play a relevant role, optimizing routes and adjusting parameters in real time. From a clinical perspective, this translates into a hybrid model in which the surgeon maintains strategic oversight of the procedure, while the system executes automatic micro-adjustments with a precision difficult to achieve manually.

Despite the technological potential, the transition to clinical practice involves overcoming a series of complex challenges that cannot be underestimated. First, safety validation is fundamental: any device navigating within the urinary system must demonstrate that it does not cause mucosal injury, obstruction, or become lodged in the body. This is especially critical given the small scale of microrobots and the potential difficulty of retrieval. Furthermore, it will be necessary to establish standardized clinical protocols that precisely define variables such as patient positioning, the intensity and configuration of magnetic fields, as well as the duration and sequence of the procedure. Compatibility with imaging systems also presents a technical challenge, as interference must be minimized and, in the case of radiation-based techniques, cumulative exposure for both the patient and the medical team must be reduced. From a regulatory perspective, these devices will have to undergo the complete clinical validation process, including phase I, II, and III trials, before obtaining approval from agencies such as the FDA, Health Canada, or the European Medicines Agency. Added to this is the economic evaluation, where factors such as the cost of implementation, equipment maintenance and the learning curve of medical personnel will play a decisive role in its adoption.

If these systems achieve clinical maturity, their impact could extend far beyond the treatment of kidney stones. The ability to guide microscale devices within the human body opens up a range of applications in precision medicine. For example, it would be possible to deliver targeted therapies to tumors through the localized release of drugs or the application of controlled hyperthermia, increasing efficacy and reducing systemic side effects. Similarly, in the vascular field, these devices could be used to remove microthrombi in hard-to-reach areas, offering an alternative to more invasive procedures. Another promising area is focal biopsy, where microrobots could obtain tissue samples with unprecedented precision, even from small or complexly located lesions. Taken together, these applications position microrobotics as a key technological driver in the evolution toward highly personalized, minimally invasive interventions, characterized by extremely precise spatial control and deep integration between engineering and clinical medicine.

There is still no universally approved standard urine test for routinely screening for pancreatic or prostate cancer, but there are robust lines of research, clinical trials, and peer-reviewed studies showing promising results. In particular, the detection of urinary biomarkers has become one of the most active areas of precision diagnostic medicine. The narrative of “robots that remove kidney stones without surgery” is a plausible projection supported by real advances in magnetic microrobotics. However, it is not yet a clinical standard. The field is advancing rapidly, and if its safety and efficacy are confirmed, it could redefine interventional urology, reducing trauma and improving outcomes in complex scenarios.